Locations
San Francisco, CA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series A
founded in
2020
Switch Therapeutics is an emerging precision neuroscience biotechnology company focused on developing innovative genetic medicines using their proprietary Conditionally Activated si RNA (CASi) platform. This platform combines the advantageous properties of single and double-stranded RNA, allowing for efficient self-delivery and uptake, as well as potent and durable knockdown. Their initial focus is on treating central nervous system diseases with high unmet needs, positioning them uniquely in the RNAi therapy market. The company aims to improve therapeutic windows for existing targets and explore numerous therapeutic applications, making them a promising player in the biotechnology sector.
Something looks off?